StockNews.com began coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) in a research note released on Thursday morning. The firm issued a buy rating on the biopharmaceutical company’s stock. Other equities analysts also recently issued reports about the stock. Sanford C. Bernstein began coverage on shares of Alnylam Pharmaceuticals in a research note […]
Treasurer of the State of North Carolina grew its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 2.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 86,367 shares of the biopharmaceutical company’s stock after buying an […]
BMO Capital Markets upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) from a market perform rating to an outperform rating in a research report sent to investors on Friday, The Fly reports. The brokerage currently has $250.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $200.00. Several other […]
California Public Employees Retirement System raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 0.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 270,883 shares of the biopharmaceutical company’s stock after acquiring an additional 1,123 shares during the […]
BMO Capital Markets upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) from a market perform rating to an outperform rating in a research report report published on Friday, The Fly reports. They currently have $250.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $200.00. Other analysts also recently […]